Free Trial

Hyperfine (HYPR) to Release Quarterly Earnings on Tuesday

Hyperfine logo with Medical background

Hyperfine (NASDAQ:HYPR - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Tuesday, May 13th. Analysts expect Hyperfine to post earnings of ($0.12) per share and revenue of $2.82 million for the quarter. Hyperfine has set its FY 2025 guidance at EPS.

Hyperfine (NASDAQ:HYPR - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The business had revenue of $2.32 million during the quarter, compared to analysts' expectations of $2.30 million. Hyperfine had a negative net margin of 309.42% and a negative return on equity of 57.54%. During the same quarter in the previous year, the company earned ($0.15) earnings per share. On average, analysts expect Hyperfine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Hyperfine Trading Up 3.5 %

HYPR stock traded up $0.03 during midday trading on Friday, reaching $0.74. The stock had a trading volume of 776,586 shares, compared to its average volume of 392,765. The company has a market cap of $57.93 million, a price-to-earnings ratio of -1.31 and a beta of 1.04. Hyperfine has a 52-week low of $0.58 and a 52-week high of $1.90. The company's fifty day simple moving average is $0.77 and its 200 day simple moving average is $0.93.

Wall Street Analyst Weigh In

Several analysts have recently commented on HYPR shares. Lake Street Capital assumed coverage on shares of Hyperfine in a research report on Monday, March 24th. They set a "buy" rating and a $1.50 price target on the stock. B. Riley decreased their price target on Hyperfine from $1.50 to $1.20 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Finally, Wells Fargo & Company raised their price objective on Hyperfine from $1.10 to $1.29 and gave the stock an "equal weight" rating in a research report on Tuesday, March 18th.

Read Our Latest Stock Report on Hyperfine

About Hyperfine

(Get Free Report)

Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.

Recommended Stories

Earnings History for Hyperfine (NASDAQ:HYPR)

Should You Invest $1,000 in Hyperfine Right Now?

Before you consider Hyperfine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hyperfine wasn't on the list.

While Hyperfine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines